DOI

  • Alexander D. Makatsariya
  • Gian C. Di Renzo
  • Giuseppe Rizzo
  • Viktoria O. Bitsadze
  • Jamilya Kh Khizroeva
  • Dmitry V. Blinov
  • Elena I. Vovk
  • Igor E. Govorov
  • Dmitry L. Guryev
  • Galina B. Dikke
  • Marina S. Zainulina
  • Natalya S. Zakharova
  • Vladislav V. Kovalev
  • Vladimir A. Kramarskiy
  • Alexander B. Loginov
  • Larisa I. Maltseva
  • Vyacheslav B. Nemirovskiy
  • Dmitry A. Ponomarev
  • Elena B. Rudakova
  • Natalia V. Samburova
  • Olga F. Serova
  • Faina K. Tetelyutina
  • Maria V. Tretyakova
  • Jumber Yu Ungiadze
  • Valentina I. Tsibizova

An issue of habitual miscarriage poses a high social importance especially during COVID-19 pandemic. Meanwhile, healthcare workers faced a mass media campaign against using micronized progesterone upon habitual miscarriage, which, as viewed by us, displays signs of prejudiced data manipulation and may disorient practitioners. In this Letter we provide objective information on accumulated data regarding gestagenes efficacy and safety. We invoke healthcare professionals to make decisions deserving independent primary source trust presented by original scientific papers published in peer-reviewed journals, clinical recommendations proposed by professional medical communities as well as treatment standards and protocols.

Переведенное названиеRegarding the evidence-based use of micronized progesterone
Язык оригиналарусский
Страницы (с-по)374-383
Число страниц10
ЖурналObstetrics, Gynecology and Reproduction
Том14
Номер выпуска3
DOI
СостояниеОпубликовано - 2020

    Области исследований

  • Didrogesterone, Evidence base, Gestagenes, Habitual miscarriage, Progesterone

    Предметные области Scopus

  • Репродуктивная медицина
  • Эмбриология
  • Акушерство и гинекология

ID: 87783955